NOVO NORDISK A/S-B (NONOF:OTCMKTS)
$50.125 0.8775 (1.7818%)
Analysed NOVO NORDISK A/S-B (NONOF:OTCMKTS) News Sources
Novo Nordisk Stock Rises After Wegovy Pill Captured 89% of U.S. Prescriptions
15-07-2026
yahoo.com
Vivani Medical Eyes August Human Trial for Semaglutide Implant After Novo Nordisk Deal
15-07-2026
marketbeat.com
Novo Nordisk (CPSE:NOVO B) Stock Fair Value Edges Higher As Analysts Rework Growth Assumptions
15-07-2026
yahoo.com
Bear of the Day: General Mills (GIS)
16-07-2026
yahoo.com
The Next Wave Of Peptides Could Be Here; What Does It Mean For Lilly, Novo?
16-07-2026
yahoo.com
Pfizer Stock Below 50-Day and 200-Day SMA: Buy the Dip or Exit Now?
16-07-2026
yahoo.com
European Equities Traded in the US as American Depositary Receipts Edge Lower Thursday
16-07-2026
yahoo.com
Novo secures European approval for oral Wegovy to extend lead over Lilly
16-07-2026
pharmaceutical-technology.com
NVO Stock Up on EC Approval of Wegovy Pill to Treat Obesity
16-07-2026
yahoo.com
Novo Nordisk (NYSE:NVO) Wins First EU Approval For Oral Wegovy In Weight Management
16-07-2026
yahoo.com
What is the current price of NOVO NORDISK A/S-B (NONOF:OTCMKTS)?
The current price of NOVO NORDISK A/S-B (NONOF:OTCMKTS) is $50.125.
NOVO NORDISK A/S-B (NONOF:OTCMKTS) absolute price change since previous trading day?
The absolute price change of NOVO NORDISK A/S-B (NONOF:OTCMKTS) since the previous trading day is $0.8775.
NOVO NORDISK A/S-B (NONOF:OTCMKTS) percentage price change since previous trading day?
The percentage price change of NOVO NORDISK A/S-B (NONOF:OTCMKTS) since the previous trading day is 1.7818%.
What is the most recent average sentiment score for NOVO NORDISK A/S-B (NONOF:OTCMKTS)?
The most recent average sentiment score for NOVO NORDISK A/S-B (NONOF:OTCMKTS) is 47 out of 100.
What is the most recent average sentiment for NOVO NORDISK A/S-B (NONOF:OTCMKTS)?
The most recent sentiment for NOVO NORDISK A/S-B (NONOF:OTCMKTS) is .
SEC-8K** Filing Available For NOVO NORDISK A/S-B (NONOF:OTCMKTS)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.